Search
Showing results for "Wal yan"
A study published in Science Advances has revealed that while genetics play a significant role in shaping children's immune systems, environmental factors also influence key immune responses, offering opportunity for preventing allergic diseases.
Patients with lung infections that are not responding to antibiotics will be treated with phage therapy as part of a translational trial program to be undertaken by world-recognised experts in this field.
The AERIAL study, in partnership with The ORIGINS Project, endeavours to understand if exposures during pregnancy and early life can affect the cells lining the airways in newborns, and whether this is associated with the development of wheeze, allergy and asthma later in childhood.
Information about cystic fibrosis awareness month and CF research at The Kids
A $350,000 Cure4 Cystic Fibrosis grant is set to propel the Wal-yan Respiratory Research Centre’s Phage WA program forward, supercharging its fight against antimicrobial resistant (AMR) lung infections in people with Cystic Fibrosis (CF) using cutting-edge phage therapy.
A promising new treatment pioneered in Western Australia for people with cystic fibrosis has commenced testing in a clinical trial in the United States and Australia.
Perth researchers have found toxic and harmful chemicals in several dozen e-cigarette liquids readily available in Australia.
Dr Kak-Ming Ling, a Wal-yan Respiratory researcher at the Kids Research Institute Australia, has been awarded a $25,000 Illuminate Award for her work to change that. Supported by Conquer Cystic Fibrosis, the award was presented at the 2026 Illuminate PitchFest hosted by The Kids.
The agenda of sessions for day two
New hope is on the horizon for people living with cystic fibrosis.